WHO ICTRP trial
A PHASE I STUDY OF CASIRIVIMAB AND IMDEVIMAB IN JAPANESE ADULT VOLUNTEERS
JPRN-jRCT2071200117 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2071200117 |
|---|---|
| Public title | A PHASE I STUDY OF CASIRIVIMAB AND IMDEVIMAB IN JAPANESE ADULT VOLUNTEERS |
| Scientific title | A PHASE I, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS OF CASIRIVIMAB AND IMDEVIMAB IN JAPANESE ADULT VOLUNTEERS |
| Primary sponsor | Nanki Toshihiro |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 1 |
| Conditions | coronavirus disease 2019(COVID-19) |
| Interventions | IV Cohort : A single IV dose of Casirivimab(Genetical Recombination)1200mg and Imdevimab(Genetical Recombination)1200mg, a single IV dose of Casirivimab(Genetical Recombination)4000mg and Imdevimab(Genetical Recombination)4000mg or a single… |
| Registration date | Mar 29, 2021 |
| Target size | 22 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: